Search
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigational[L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.
Omidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigational[A258948] A pooled analysis of five prospective clinical trials found that the use of omidubicel led to stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up … It is administered as a single intravenous dose specific to each patient.
Immunoglobulin heavy constant alpha 2
go.drugbank.com/bio_entities/BE0004610TargetHumansSecreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414).
Synonyms: Ig alpha-2 chain C region BUTImmunoglobulin heavy constant alpha 1
go.drugbank.com/bio_entities/BE0005097TargetHumansSecreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414).
Synonyms: Ig alpha-1 chain C region BUREnoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnTrials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Benzhydrocodone
go.drugbank.com/drugs/DB15465ApprovedIt was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862] … [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.
Anthralin
go.drugbank.com/drugs/DB11157ApprovedIt is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical … Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy [L1979].
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. … Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting
Bendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.